July 15, 2014 · Leave a Comment
Genome-Wide Associations of Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations
By Center for Individualized Medicine
Published in the British Journal of Clinical Pharmacology, a team of researchers from the Mayo Clinic, led by the director of the Center for Individualized Medicine’s Pharmacogenomics Program, Richard Weinshilboum, M.D., applied a genome-wide association study (GWAS) to identify genetic factors that contribute to variation in plasma concentrations of Citalopram (CT) or escitalopram (S-CT), and […]
View full entry Comment on this
Tags: center for individualized medicine, citalopram, DNA, DNA Sequencing, dna test, DNA Testing, escitalopram, gene sequencing, genetic, Genetics, genome, genome science
March 13, 2014 · Leave a Comment
Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations
A recently published article in the area of Pharmacogenomics set out to identify genetic factors in Citalopram (CT) and escitalopram (S-CT), which are among the most widely prescribed serotonin reuptake inhibitors (SSRIs) used to treat Major Depressive Disorder (MDD), that contribute to variation in plasma concentrations of CT or S-CT and their metabolites in MDD patients treated […]
View full entry Comment on this
Tags: citalopram, dna test, DNA Testing, escitalopram, gene sequencing, genome science, genome-wide association studies, genomic medicine, genomics, individualized medicine, major depressive disorder, personal genomics